Exicure (XCUR) Income from Continuing Operations (2016 - 2026)
Exicure's (XCUR) quarterly Income from Continuing Operations came in at 1828000.0 in Q1 2026, down 160.73% YoY from 3010000.0 in Q1 2025, and up 36.92% on a QoQ basis from 2898000.0 in Q4 2025.
Exicure (XCUR) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Income from Continuing Operations data on file, last reported at 1828000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 160.73% year-over-year to 1828000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9784000.0 (down 66.68% YoY) and the FY2025 annual result came in at 4946000.0, up 49.02% from the prior year.
- Income from Continuing Operations improved to 1828000.0 in Q1 2026, from 2898000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 18396000.0 in Q4 2022 to a low of 8348000.0 in Q1 2022.
- A 5-year average of 2116411.76 and a median of 2621000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 383.46% — and 2025, when it jumped 463.09%.
- Tracing XCUR's Income from Continuing Operations over 5 years: stood at 18396000.0 in 2022, then slumped by 108.08% to 1487000.0 in 2023, then tumbled by 383.46% to 7189000.0 in 2024, then jumped by 59.69% to 2898000.0 in 2025, then surged by 36.92% to 1828000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1828000.0 (Q1 2026), 2898000.0 (Q4 2025), and 2437000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Dec 31, 2024 | -7.19 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -600,000.00 |
| Mar 31, 2024 | -829,000.00 |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | -5.26 Mn |
| Jun 30, 2023 | -5.76 Mn |
| Mar 31, 2023 | -4.41 Mn |
| Dec 31, 2022 | 18.40 Mn |
| Sep 30, 2022 | -5.16 Mn |
| Jun 30, 2022 | -7.47 Mn |
| Mar 31, 2022 | -8.35 Mn |
| Dec 31, 2021 | -13.83 Mn |
| Sep 30, 2021 | -23.53 Mn |
| Jun 30, 2021 | -14.27 Mn |